72results about How to "Reducing and preventing effect" patented technology

A reference voltage supply apparatus and a driving method thereof in a ferroelectric memory device provide a reference voltage stabilized against the imprint effect thus maintaining reading reliability of the device. In the reference voltage supply apparatus (e.g., using a non-switching capacitance of a ferroelectric capacitor), a reference cell is constructed of a ferroelectric capacitor and an access switch, and provides a reference voltage to read data from a memory cell. In an active mode, the reference cell stores data of a first logic state (e.g., corresponding to the non-switching capacitance of the ferroelectric capacitor), in the reference cell, and then supplies, as a reference voltage, the voltage corresponding to the data of the first logic state to a bit line; and in a stand-by mode, a reference voltage controller stores (writes) data of a second logic state (opposite to the first logic state), into the reference cell.

A damascene structure for semiconductor devices is provided. In an embodiment, the damascene structure includes trenches formed over vias that electrically couple the trenches to an underlying conductive layer such that the trenches have varying widths. The vias are lined with a first barrier layer. The first barrier layers along the bottom of vias are removed such that a recess formed in the underlying conductive layer. The recesses formed along the bottom of vias are such that the recess below narrower trenches is greater than the recess formed below wider trenches. In another embodiment, a second barrier layer may then be formed over the first barrier layer. In this embodiment, a portion of the conductive layer may be interposed between the first barrier layer and the second barrier layer.

A process for inhibiting vascular proliferation separately introduces components into the eye to generate plasmin in the eye in amounts to induce complete posterior vitreous detachment where the vitreoretinal interface is devoid of cortical vitreous remnants. The process administers a combination of lysine-plasminogen, at least one recombinant plasminogen activator selected from the group consisting of urokinase, streptokinase, tissue plasminogen activator, chondroitinase, pro-urokinase, retavase, metaloproteinase, and thermolysin and a gaseous adjuvant to form a cavity in the vitreous. The composition is introduced into the vitreous in an amount effective to induce crosslinking of the vitreous and to induce substantially complete posterior vitreous detachment from the retina without causing inflammation of the retina. The gaseous adjuvant material is introduced into the vitreous simultaneously with or after the lysine-plasminogen and recombinant plasminogen activator such as recombinant urokinase to compress the vitreous against the retina while the composition induces the complete posterior vitreous detachment.

The subject invention relates to novel micoparticulate and soluble forms of flavonoids, and their synthesis. The invention also includes novel formulations of such flavonoids. Further, the invention includes novel methods of manufacturing the flavonoid formulations. The invention also relates to a wide variety of applications of the flavonoid formulations.

The present invention relates to a method and controller for heating a wind turbine blade that comprises a plurality of heating zones. An icing factor is determined based on environmental conditions and one or more heating zones are determined based on the determined icing factor, wherein each heating zone comprises one or more Electro-Thermal Heating Elements. The one or more Electro-Thermal Heating Elements corresponding to the determined heating zones are activated to generate heat.

A liquid crystal cell (5) comprises a layer (4) of cholesteric liquid crystal material; and a retarder (3) disposed in an optical path through the layer (4) of cholesteric liquid crystal material. The cholesteric liquid crystal material is switchable between a first state in which it cooperates with the retarder (3) to provide a first viewing angle range and a second state in which it cooperates with the retarder (3) to provide a second viewing angle range which is smaller than the first viewing angle range. The pitch of the cholesteric liquid crystal material is greater than an intended wavelength of operation of the liquid crystal cell divided by the average refractive index of the liquid crystal material. The liquid crystal cell may be used as a Viewing Angle Restriction (VAR) element, to enable another component, such as a display panel (6), to be operated in either a wide viewing mode or a narrow viewing mode.

The present invention relates to a formulation comprising an inhibitor of NFAT activation for use in treating or preventing undesirable effects, more particularly undesirable effects occurring in conjunction with T cell-mediated therapies. The undesirable effects may be cytokine release syndrome (CRS) or symptoms associated with gastrointestinal (GI) inflammation, for example associated with inflammatory bowel diseases, such as ulcerative colitis, optionally caused by activated T cell activity. In addition to ameliorating undesirable effects, the invention is aimed at also maintaining the therapeutic effects of the T-cell mediated therapy.

Provided are uses of erythropoietin, or a derivative or functional analogue thereof, for the production of a medicament for the preventive or curative treatment of patients suffering from, or at risk of suffering from, cardiac failure.

Provided are methods for treating a mammal undergoing sepsis, or at risk for sepsis. Also provided are methods of preventing or treating a physiological effect of sepsis in a mammal. Additionally provided are methods of inhibiting an inflammatory response in a mammal. Further provided is the use of an α_2A-adrenergic antagonist for the manufacture of a medicament for preventing or treating a physiologic effect of sepsis in a mammal, and the use of an α_2A-adrenergic antagonist for the treatment of a mammal having sepsis or at risk for sepsis.

The invention pertains to a biocompatible composition, suitable for use in soft or hard tissue augmentation, wherein the composition is an aqueous suspension containing a carrier fraction of ceramic particles of less than 15 &mgr;m and an augmentation fraction of ceramic particles of at least 20 &mgr;m. The ceramics typically comprise calcium phosphate. The composition is a may be used in soft tissue repair as well as hard bone replacement. It advantageously avoids the need for foreign body materials which are conventionally applied to stabilize augmentation suspensions.